4.4684  0.098 (2.25%)		04-25 16:00
Open: 4.505 High: 4.6009 Volume: 2,336		Pre. Close: 4.37 Low: 4.4555 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	5.79	1-year :	6.76
Resists	First :	4.96	Second :	5.79
Pivot price	4.45
Supports	First :	4.32	Second :	3.93
MAs	MA(5) :	4.41	MA(20) :	4.44
	MA(100) :	4.59	MA(250) :	5.04
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	35	D(3) :	35.2
RSI	RSI(14): 50.7
52-week	High :	8.6	Low :	2.46

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EDSA ] has closed below upper band by 47.9%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	4.61 - 4.63	4.63 - 4.65
Low:	4.4 - 4.43	4.43 - 4.45
Close:	4.43 - 4.47	4.47 - 4.5

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Thu, 11 Apr 2024
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference - Yahoo Finance

Tue, 02 Apr 2024
Edesa Biotech to Participate in Upcoming Investor Conferences - Chronicle-Tribune

Mon, 25 Mar 2024
Edesa Biotech CEO acquires $20k in company shares - Investing.com

Fri, 01 Mar 2024
EDSA Stock Quote Price and Forecast - CNN

Fri, 15 Dec 2023
Edesa Biotech Reports Fiscal Year 2023 Results - Yahoo Finance

Mon, 20 Nov 2023
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	2 (M)
Held by Insiders	28.3 (%)
Held by Institutions	10.7 (%)
Shares Short	20 (K)
Shares Short P.Month	17 (K)

EPS	-20.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.85
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-55.8 %
Return on Equity (ttm)	-95.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.67
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.23
PEG Ratio	0
Price to Book value	2.41
Price to Sales	0
Price to Cash Flow	-2.31

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.